Many clinical studies have been conducted to assess the ability of renin-angiotensin aldosterone system (RAAS) blockade to lower blood pressure and reduce end-organ damage. Direct renin inhibitors (DRI) have emerged as an attractive option to inhibit the RAAS and thus prevent cardiovascular damage. In this review, we examine the data related to the administration of the DRI, aliskiren, as an antihypertensive agent and describe the most recent publications assessing the effects of aliskiren on end-organ protection.

